Concomitant prescribing of opioids and benzodiazepines in Australia, 2012–2017

Gillian E. Caughey; Svetla Gadzhanova; Sepehr Shakib; Elizabeth E. Roughead

doi:10.5694/mja2.12026

Concomitant prescribing of opioids and benzodiazepines in Australia, 2012–2017

Gillian E. Caughey, Svetla Gadzhanova, Sepehr Shakib, Elizabeth E. Roughead

Research output: Contribution to journal › Letter › peer-review

9 Citations (Scopus)

Abstract

Studies in the United States have raised concerns about the increasing concomitant prescribing of opioids and benzodiazepines and the incidence of associated serious harms, including respiratory depression, hospitalisation, and death.1-3 As a result, and following their own 2016 review, the Food and Drug Administration decided that opioid and benzodiazepine medications in the US must include boxed warnings about possible serious side-effects.4 Whether concomitant prescribing has also increased in Australia is unknown.

Original language	English
Pages (from-to)	39-40
Number of pages	2
Journal	Medical Journal of Australia
Volume	210
Issue number	1
DOIs	https://doi.org/10.5694/mja2.12026
Publication status	Published - Jan 2019
Externally published	Yes

Keywords

Opioid prescribing
Concomitant medications
Concomitant benzodiazepine
benzodiazepines
side effects
Australia
FDA

Access to Document

10.5694/mja2.12026Licence: In Copyright

Cite this

@article{80c927828d6e46ab8d366fa499f496bf,

title = "Concomitant prescribing of opioids and benzodiazepines in Australia, 2012–2017",

abstract = "Studies in the United States have raised concerns about the increasing concomitant prescribing of opioids and benzodiazepines and the incidence of associated serious harms, including respiratory depression, hospitalisation, and death.1-3 As a result, and following their own 2016 review, the Food and Drug Administration decided that opioid and benzodiazepine medications in the US must include boxed warnings about possible serious side-effects.4 Whether concomitant prescribing has also increased in Australia is unknown.",

keywords = "Opioid prescribing, Concomitant medications, Concomitant benzodiazepine, benzodiazepines, side effects, Australia, FDA",

author = "Caughey, {Gillian E.} and Svetla Gadzhanova and Sepehr Shakib and Roughead, {Elizabeth E.}",

year = "2019",

month = jan,

doi = "10.5694/mja2.12026",

language = "English",

volume = "210",

pages = "39--40",

journal = "Medical Journal of Australia",

issn = "0025-729X",

publisher = "Australasian Medical Publishing Company Ltd.",

number = "1",

}

TY - JOUR

T1 - Concomitant prescribing of opioids and benzodiazepines in Australia, 2012–2017

AU - Caughey, Gillian E.

AU - Gadzhanova, Svetla

AU - Shakib, Sepehr

AU - Roughead, Elizabeth E.

PY - 2019/1

Y1 - 2019/1

N2 - Studies in the United States have raised concerns about the increasing concomitant prescribing of opioids and benzodiazepines and the incidence of associated serious harms, including respiratory depression, hospitalisation, and death.1-3 As a result, and following their own 2016 review, the Food and Drug Administration decided that opioid and benzodiazepine medications in the US must include boxed warnings about possible serious side-effects.4 Whether concomitant prescribing has also increased in Australia is unknown.

AB - Studies in the United States have raised concerns about the increasing concomitant prescribing of opioids and benzodiazepines and the incidence of associated serious harms, including respiratory depression, hospitalisation, and death.1-3 As a result, and following their own 2016 review, the Food and Drug Administration decided that opioid and benzodiazepine medications in the US must include boxed warnings about possible serious side-effects.4 Whether concomitant prescribing has also increased in Australia is unknown.

KW - Opioid prescribing

KW - Concomitant medications

KW - Concomitant benzodiazepine

KW - benzodiazepines

KW - side effects

KW - Australia

KW - FDA

UR - http://www.scopus.com/inward/record.url?scp=85059909763&partnerID=8YFLogxK

UR - http://purl.org/au-research/grants/NHMRC/1040938

U2 - 10.5694/mja2.12026

DO - 10.5694/mja2.12026

M3 - Letter

C2 - 30636298

AN - SCOPUS:85059909763

SN - 0025-729X

VL - 210

SP - 39

EP - 40

JO - Medical Journal of Australia

JF - Medical Journal of Australia

IS - 1

ER -

Concomitant prescribing of opioids and benzodiazepines in Australia, 2012–2017

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this